Phase II Study of ZIO-101 in Advanced Blood and Bone Marrow Cancers

• Status: Completed
• Trial end date: 2012-04-01
• Target enrollment: 0
• Participant gender: All

Summary

The study of safety of a new organic arsenic compound in the treatment of hematological malignancies.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Ziopharm

Criteria

Inclusion Criteria

1. Hodgkin's or non-Hodgkin's Lymphoma.

2. ≥ 1 prior therapy and currently requiring therapy.

3. Evaluable disease (defined by disease-specific criteria listed in Appendix 1)

4. ≥ 18 years of age.

5. ECOG performance score ≤ 2 (see Appendix 2).

6. Life-expectancy ≥ 2 months.

7. Written informed consent in compliance with ZIOPHARM policies and the Human Investigation Review Committee with jurisdiction over the site.

8. No anti-cancer therapy exception of hydroxyurea ≤ 3 weeks before Baseline (Day 1, Cycle 1).

9. The following clinical laboratory values < 2 weeks before Baseline:

• Creatinine ≤ 2X upper limit of normal (ULN).

• Total bilirubin ≤ 2X ULN.

• Alanine transaminase (ALT) and aspartate transaminase (AST) ≤ 3X ULN.

Exclusion Criteria

1. New York Heart Association (NYHA) functional class ≥3 myocardial infarction (see Appendix ) within 6 months before Baseline or uncontrolled cardiac arrhythmia other than asymptomatic atrial fibrillation; a QTc ≥450 msec; or a ≥grade-2 atrioventricular (AV) block or left bundle branch block (LBBB).

2. Pregnant and/or lactating female. (Women of childbearing age must use effective contraception from Screening through the duration of study participation).

3. Uncontrolled infection.

4. Prior seizures ≥ grade-3 in CTC v.3 criteria.

5. Arsenic allergy.

6. Significant neuropathology, defined as grade > 2 per CTCAE Version 3.0.

7. Confusion or dementia.

8. Prior history of neurological deficits (e.g., stroke, dementia, ischemia) that has the potential to confound a post-dose neurological assessment.